OXFORD,
England, April 29, 2024 /PRNewswire/
-- Caristo Diagnostics, a leading cardiac
disease diagnostics company, has been named by
Newsweek as one of World's Best Digital Health
Companies in diagnostics.
Newsweek's inaugural ranking of the World's Best Digital
Health Companies includes 400 companies in seven segments including
diagnostics, health records, medical management and telehealth. The
ranking is based on in-depth analysis of thousands of companies'
financial performance and traffic data for websites and apps. In
addition, market intelligence company Holon IQ provided data on the
impact of companies' innovations and the expertise of their
leadership.
"Caristo is honored to be recognized by Newsweek as one
of the World's Best Digital Health Companies. This recognition
validates the importance of Caristo's CaRi-Heart® innovation
as it for the first time gives healthcare professionals the ability
to measure inflammation in the heart," said Frank Cheng, CEO of Caristo. "This
recognition also speaks to the dedication and ingenuity of our team
as well as our scientific, clinical and pharmaceutical industry
partners around the world, who continuously push the boundaries to
seek more effective ways to prevent, diagnose and treat coronary
artery diseases."
Caristo's patented CaRi-Heart technology marks a novel
scientific breakthrough that is radically transforming the
traditional approach to heart disease prediction, prevention and
management. The technology applies advanced AI algorithms to
routine coronary computed tomography angiography (CCTA) scans to
visualize and quantify coronary inflammation, the otherwise
invisible disease responsible for many fatal heart attacks and
strokes. The CaRi-Heart technology has been shown to predict
fatal and non-fatal cardiac events independently from routine
clinical risk scores and standard CCTA interpretation, and can
significantly impact treatment for coronary artery disease by
transforming risk stratification and management of patients. Since
2018, exceptional validation results showing the CaRi-Heart
technology's ability to aid the prediction of heart attacks have
been published in leading medical journals including the Lancet,
JACC, European Heart Journal, and Cardiovascular Research.
The CaRi-Heart® technology is in clinical use in the UK,
European Union and Australia.
About Caristo Diagnostics
Caristo Diagnostics is a global leader in cardiac and
vascular disease diagnostics and risk prediction. Founded in 2018
as a spin-out company from the University of
Oxford, the world's #1 research university, Caristo has
developed a portfolio of imaging-based and AI-assisted platforms
that can be applied to aid the prediction and diagnosis of heart
attack, stroke, and diabetes. Caristo has been recognized by
Newsweek as one of the best digital health companies, and
highlighted by Nature as one of the most exciting science-based companies to have emerged
from academic labs. Find Caristo online on its website,
LinkedIn and X.
Caristo Diagnostics contact:
Frank Cheng,
CEO
info@caristo.com
Logo:
https://mma.prnewswire.com/media/2054669/4675723/Caristo_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/newsweek-selects-caristo-diagnostics-as-one-of-worlds-best-digital-health-companies-302129789.html
SOURCE Caristo Diagnostics